// App-Quantinova.ai

305 : Phase II study of neoadjuvant sorafenib plus cisplatin and gemcitabine (S-CG) for patients with muscle-invasive transitional cell carcinoma of the bladder (MIBC): Results at the end of first stage (NCT01222676).

Researchers

Presenter

  • Andrea Necchi

Principal Investigators

  • Luigi Mariani

  • Tullio Torelli

  • Silvia Stagni

  • Massimo Maffezzini

  • Maurizio Colecchia

  • Biagio Paolini

  • Vera Cappelletti

  • Maria Grazia Daidone

  • Alessandro M. Gianni

  • Roberto Salvioni

  • Emanuela Fina

  • Nicola Nicolai

  • Marzia Pennati

  • Nadia Zaffaroni

  • Elena Fare

  • Luigi Piva

  • Davide Biasoni

  • Mario Catanzaro

Medical Centers

  • Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Transitional cell carcinoma of the bladder

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Gemcitabine

  • Cisplatin

  • Sorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01222676

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved